메뉴 건너뛰기




Volumn 130, Issue 3, 2012, Pages 735-742

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

(18)  Terpos, Evangelos a   Anargyrou, Konstantinos b   Katodritou, Eirini c   Kastritis, Efstathios a   Papatheodorou, Athanasios b   Christoulas, Dimitrios a   Pouli, Anastasia d   Michalis, Eurydiki e   Delimpasi, Sosana f   Gkotzamanidou, Maria a   Nikitas, Nikitas a   Koumoustiotis, Vasilios b   Margaritis, Dimitrios g   Tsionos, Konstantinos b   Stefanoudaki, Ekaterini h   Meletis, John a   Zervas, Konstantinos c   Dimopoulos, Meletios A a  


Author keywords

angiogenesis; angiopoietin 1; angiopoietin 2; multiple myeloma; survival

Indexed keywords

ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BORTEZOMIB; FIBROBLAST GROWTH FACTOR 2; THALIDOMIDE; VASCULOTROPIN;

EID: 82255191895     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26062     Document Type: Article
Times cited : (27)

References (25)
  • 3
    • 42049084260 scopus 로고    scopus 로고
    • Novel anti-myeloma agents and angiogenesis
    • DOI 10.1080/10428190701861686, PII 790630458
    • Anargyrou K, Dimopoulos MA, Sezer O, Terpos E,. Novel anti-myeloma agents and angiogenesis. Leuk Lymphoma, 2008; 49: 677-89. (Pubitemid 351517212)
    • (2008) Leukemia and Lymphoma , vol.49 , Issue.4 , pp. 677-689
    • Anargyrou, K.1    Dimopoulos, M.-A.2    Sezer, O.3    Terpos, E.4
  • 4
    • 0344844433 scopus 로고    scopus 로고
    • Clinician Guide to Angiogenesis
    • DOI 10.1161/01.CIR.0000102939.04279.75
    • Fam NP, Verma S, Kutryk M, Stewart DJ,. Clinician guide to angiogenesis. Circulation 2003; 108: 2613-8. (Pubitemid 37466800)
    • (2003) Circulation , vol.108 , Issue.21 , pp. 2613-2618
    • Fam, N.P.1    Verma, S.2    Kutryk, M.3    Stewart, D.J.4
  • 6
    • 0037311029 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and angiopoietin-2 in myeloma cells
    • Uneda S, Matsuno F, Sonoki T, Tniguchi I, Kawano F, Hata H,. Expression of vascular endothelial factor and angiopoietin-2 in myeloma cells. Haematologica 2003; 88: 113-5. (Pubitemid 36168864)
    • (2003) Haematologica , vol.88 , Issue.1 , pp. 113-115
    • Uneda, S.1    Matsuno, F.2    Sonoki, T.3    Tniguchi, I.4    Kawano, F.5    Hata, H.6
  • 8
    • 57849161431 scopus 로고    scopus 로고
    • The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    • Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA,. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-56.
    • (2008) Leukemia , vol.22 , pp. 2247-2256
    • Terpos, E.1    Kastritis, E.2    Roussou, M.3    Heath, D.4    Christoulas, D.5    Anagnostopoulos, N.6    Eleftherakis-Papaiakovou, E.7    Tsionos, K.8    Croucher, P.9    Dimopoulos, M.A.10
  • 10
    • 45749091430 scopus 로고    scopus 로고
    • Individualizing treatment of patients with myeloma in the era of novel agents
    • San-Miguel J, Harousseau JL, Joshua D, Anderson KC,. Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol 2008; 26: 2761-6.
    • (2008) J Clin Oncol , vol.26 , pp. 2761-2766
    • San-Miguel, J.1    Harousseau, J.L.2    Joshua, D.3    Anderson, K.C.4
  • 15
    • 57849161431 scopus 로고    scopus 로고
    • The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    • Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA,. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-56.
    • (2008) Leukemia , vol.22 , pp. 2247-2256
    • Terpos, E.1    Kastritis, E.2    Roussou, M.3    Heath, D.4    Christoulas, D.5    Anagnostopoulos, N.6    Eleftherakis-Papaiakovou, E.7    Tsionos, K.8    Croucher, P.9    Dimopoulos, M.A.10
  • 17
    • 33748769772 scopus 로고    scopus 로고
    • Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia
    • Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, Berdel WE, Mesters RM,. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006; 91: 1203-11. (Pubitemid 44408430)
    • (2006) Haematologica , vol.91 , Issue.9 , pp. 1203-1211
    • Schliemann, C.1    Bieker, R.2    Padro, T.3    Kessler, T.4    Hintelmann, H.5    Buchner, T.6    Berdel, W.E.7    Mesters, R.M.8
  • 20
    • 0036122019 scopus 로고    scopus 로고
    • Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma
    • DOI 10.1046/j.0007-1048.2002.03364.x
    • Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E,. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116: 796-802. (Pubitemid 34226998)
    • (2002) British Journal of Haematology , vol.116 , Issue.4 , pp. 796-802
    • Iwasaki, T.1    Hamano, T.2    Ogata, A.3    Hashimoto, N.4    Kitano, M.5    Kakishita, E.6
  • 22
    • 25144517719 scopus 로고    scopus 로고
    • The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma
    • DOI 10.1002/hon.738
    • Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K,. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematol Oncol 2004; 22: 159-68. (Pubitemid 41342407)
    • (2004) Hematological Oncology , vol.22 , Issue.4 , pp. 159-168
    • Hatjiharissi, E.1    Terpos, E.2    Papaioannou, M.3    Hatjileontis, C.4    Kaloutsi, V.5    Galaktidou, G.6    Gerotziafas, G.7    Christakis, J.8    Zervas, K.9


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.